Focus on Oral, Head, Neck & Thyroid Cancers
FDA Approves Cometriq to Treat Rare Type of Thyroid Cancer
The FDA completed review of Cometriq’s application in six months under the agency’s priority review program. This program provides for an expedited six-month review for drugs that may offer major advances in treatment or that provide a treatment when no adequate therapy exists. Cometriq also received orphan-product designation by the FDA because it is intended to treat a rare disease or condition.
The Oral Cancer Foundation
The Oral Cancer Foundation is a national nonprofit organization designed for advocacy and service, created to promote change and save lives through prevention, education, research, and patient support. Approximately 37,000 people in the U.S. will be diagnosed with oral cancer this year.
Radiotherapy for Head and Neck Cancer
Most types of head and neck cancer start in the cells lining the open cavities of the head and neck, such as the sinuses, nasal cavity, mouth, or throat. Other kinds of head and neck cancer can occur in the salivary glands. These glands produce the fluid, called “saliva” or spit, that keeps your mouth and throat moist.
